Information Center



                                                      發布時間2021-02-14  |  點擊率:



                                                        The International Multi-centers Phase III trials of recombinant Novel Coronavirus Vaccine(CHO Cell) (ZF2001 vaccine), sponsored by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd, are undertaken by the Center of Advance Technologies under the Ministry of Innovative Development and the Institute of Microbiology. The trials are actively ongoing in Uzbekistan, and have made initial progress, 6,829 subjects have received the first doses, and 1,634 subjects have received the second doses, so far no significant adverse events have been observed, the vaccine is safe and reliable. At the same time, results from the Phase I and Phase II clinical trials in china has demonstrated the satisfied safety profile and immunogenicity of the vaccine.

                                                        In Uzbekistan, it is now urgently called for large scale vaccinations of COVID-19 vaccines for the people, so as to achieve herd immunity of the population and control the spread of Covid-19. In this case, the Uzbekistan government is actively promoting the emergency usage authorization(EUA) of ZF2001 vaccine. In view of the contribution and efforts of the Ministry of Innovative Development of the Republic of Uzbekistan for ZF2001 vaccine development and the deep friendship both have built since the cooperation of the clinical trials, Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd will give priority to the Republic of Uzbekistan for the emergency usage vaccine supply, and also the Republic of Uzbekistan will act as a co-developing country for ZF2001 in Uzbekistan, with the priority in Uzbekistan on the cooperative production, joint commercialization, new vaccine development and scientific research.

                                                        Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd, together with the government of Uzbekistan, will jointly work on the approval of emergency usage authorization (EUA) and marketing authorization (MA) of ZF2001 vaccine in the Republic of Uzbekistan for the prevention and control of the COVID-19 in the country, so as to achieve the public health goals of Uzbekistan.

                                                        (With EUA and MA approval, ZF2001 vaccine will be distributed in the Republic of Uzbekistan under the name ZF-UZ-Vac2001.)